Lin BioScience Inc (6696.TWO)

Healthcare | Biotechnology
Income Statement (Quarterly) 2026-04-08 2025-06-30 2025-03-31 2024-06-30
Revenue 0 0 0 0
Cost of Revenue 0 0 0 9,615,000
Gross Profit 0 0 0 -9,615,000
Operating Expenses
R&D Expenses 0 0 0 0
SG&A Expenses 213,724,000 213,724,000 213,724,000 52,307,000
Operating Expenses 580,582,000 580,582,000 580,582,000 317,668,000
Operating Income -580,582,000 -580,582,000 -580,582,000 -317,668,000
Interest Expense 0 0 0 517,000
Income Before Tax -544,173,000 -544,173,000 -544,173,000 -292,171,000
Income Tax Expense 0 0 0 94,000
Net Income -313,154,000 -313,154,000 -313,154,000 -173,414,000
Per Share
EPS -3.84 -3.84 -3.84 -2.21
EPS Diluted 0.00 0.00 0.00 0.00
Income Statement (Annual) 2023-12-31
Revenue 0
Cost of Revenue 17,927,000
Gross Profit -17,927,000
Operating Expenses
R&D Expenses 0
SG&A Expenses 242,753,000
Operating Expenses 1,096,827,000
Operating Income -1,096,827,000
Interest Expense 1,212,000
Income Before Tax -1,090,542,000
Income Tax Expense -29,724,000
Net Income -687,190,000
Per Share
EPS -9.29
EPS Diluted 0.00
Balance Sheet (Quarterly) 2024-12-31 2023-12-31
Assets
Cash and Cash Equivalents 1,488,148,000 3,261,057,000
Short Term Investments 3,720,185,000 0
Net Receivables 18,922,000 0
Inventory 0 0
Total Current Assets 5,351,323,000 3,424,216,000
Property Plant Equipment 52,438,000 59,093,000
Goodwill and Intangibles 18,922,000 108,905,000
Total Assets 5,527,062,000 3,596,722,000
Liabilities
Account Payables 0 0
Short Term Debt 16,099,000 13,847,000
Total Current Liabilities 155,327,000 138,704,000
Long Term Debt 17,892,000 29,026,000
Total Liabilities 173,219,000 167,730,000
Shareholders Equity
Retained Earnings -2,906,604,000 -2,162,338,000
Total Shareholders Equity 2,854,912,000 2,137,384,000
Balance Sheet (Annual) 2024-12-31 2023-12-31
Assets
Cash and Cash Equivalents 1,488,148,000 3,261,057,000
Short Term Investments 3,720,185,000 0
Net Receivables 18,922,000 0
Inventory 0 0
Total Current Assets 5,351,323,000 3,424,216,000
Property Plant Equipment 52,438,000 59,093,000
Goodwill and Intangibles 18,922,000 108,905,000
Total Assets 5,527,062,000 3,596,722,000
Liabilities
Account Payables 0 0
Short Term Debt 16,099,000 13,847,000
Total Current Liabilities 155,327,000 138,704,000
Long Term Debt 17,892,000 29,026,000
Total Liabilities 173,219,000 167,730,000
Shareholders Equity
Retained Earnings -2,906,604,000 -2,162,338,000
Total Shareholders Equity 2,854,912,000 2,137,384,000
Cash Flow Statement (Quarterly) 2024-12-31 2023-12-31
Operating Activities
Net Income -1,328,317,000 -1,090,542,000
Depreciation & Amortization 20,210,000 17,927,000
Stock Based Compensation 291,057,000 115,154,000
Change in Working Capital 53,509,000 -80,394,000
Operating Cash Flow -1,019,301,000 -1,012,818,000
Investing Activities
Capital Expenditure -7,346,000 -1,965,000
Investments -5,818,000 -1,965,000
Investing Cash Flow -3,550,862,000 1,866,000
Financing Activities
Debt Repayment 0 0
Common Stock Issued/Repurchased 98,379,000 622,406,000
Dividends Paid 0 0
Financing Cash Flow 2,664,613,000 2,636,911,000
Summary
Free Cash Flow -1,026,647,000 -1,014,783,000
Net Change in Cash -1,772,909,000 1,615,822,000
Cash Flow Statement (Annual) 2024-12-31 2023-12-31
Operating Activities
Net Income -1,328,317,000 -1,090,542,000
Depreciation & Amortization 20,210,000 17,927,000
Stock Based Compensation 291,057,000 115,154,000
Change in Working Capital 53,509,000 -80,394,000
Operating Cash Flow -1,019,301,000 -1,012,818,000
Investing Activities
Capital Expenditure -7,346,000 -1,965,000
Investments -5,818,000 -1,965,000
Investing Cash Flow -3,550,862,000 1,866,000
Financing Activities
Debt Repayment 0 0
Common Stock Issued/Repurchased 98,379,000 622,406,000
Dividends Paid 0 0
Financing Cash Flow 2,664,613,000 2,636,911,000
Summary
Free Cash Flow -1,026,647,000 -1,014,783,000
Net Change in Cash -1,772,909,000 1,615,822,000